Home Cart Sign in  
Chemical Structure| 112900-82-0 Chemical Structure| 112900-82-0

Structure of 112900-82-0

Chemical Structure| 112900-82-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 112900-82-0 ]

CAS No. :112900-82-0
Formula : C11H16N2O
M.W : 192.26
SMILES Code : NC1=CC=C(N2CCOCC2)C(C)=C1
MDL No. :MFCD09755865
InChI Key :KNOTXXUXSBIPQW-UHFFFAOYSA-N
Pubchem ID :10607787

Safety of [ 112900-82-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 112900-82-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 14
Num. arom. heavy atoms 6
Fraction Csp3 0.45
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 61.54
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

38.49 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.92
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.35
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.04
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.12
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.69
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.42

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.13
Solubility 1.41 mg/ml ; 0.00735 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.76
Solubility 3.34 mg/ml ; 0.0174 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.61
Solubility 0.468 mg/ml ; 0.00243 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.51 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

1.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.59

Application In Synthesis of [ 112900-82-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 112900-82-0 ]
  • Downstream synthetic route of [ 112900-82-0 ]

[ 112900-82-0 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 223404-63-5 ]
  • [ 112900-82-0 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogen In ethanol; toluene Step 2: A suspension of 4-(2-methyl-4-nitro-phenyl)-morpholine (0.53g, 2.4mMol) and 10percent palladium on carbon (55mg) in 1:1 toluene : ethanol (25ml) was placed under an atmosphere of hydrogen, using standard procedures, until reaction was complete. The reaction mixture was filtered through a pad of celite, which was then washed with ethanol. The filtrates were reduced under vacuum to give 3-methyl-4- morpholin-4-yl-phenylamine as a tan solid.( 0.47g , 100percent), LC/MS: RT - 2.66, MH+ 193; No. (CDCl3) 6.82 (1H, d, J 8.2Hz) ; 6.48-6.54 (2H, m) ; 3.76 (4H, t, J 4.4Hz) ; 2.76 (4H, t, J 4.4Hz); 2.18 (3H, s)
96.35% With ammonium chloride; zinc In methanol at 0 - 20℃; for 1 h; To a stirred mixture of 4-(2-methyl-4-nitrophenyl)morpholine (6 g, 0.0645 mol, 1.0 eq), Zn dust (8.64 g, 0.135 mol, 5 eq) in methanol (50 mL) in a round bottomed flask at 0°C, ammonium chloride (7.29 g, 0.135 mol, 5 eq) was added slowly and the mixture stirred at rt for 1 h while monitoring by TLC. After completion of the starting material, the reaction mass was filtered through a Celite® bed and filtrate was concentrated under reduced pressure to obtain a residue. The residue was diluted with DCM (150 mL) and washed with water. The organic layer was separated, washed with brine sol, dried over sodium sulphate and concentrated under reduced pressure to obtain 3-methyl-4- morpholinoaniline as brown solid (5 g, 96.35percent). 1H NMR (400 MHz, CDC13): δ 6.768 (d, 1H), 6.39 (s, 1H), 6.36 (d, 1H), 4.66 (brs, 2H), 3.681 (t, 4H), 2.683 (t, 4H), 2.124 (s, 3H).
86% With hydrogenchloride; iron In ethanol; water at 90℃; for 12 h; Inert atmosphere 4-(2-Methyl-4-nitrophenyl)morpholine (2.60 g, 11.70 mmol), iron powder (3.28 g, 58.50 mmol), BAlcohol (40mL), water (5mL) and hydrochloric acid (0.1g, 35percent aqueous solution) were added to a 100mL single-mouth bottle, heated under nitrogen and heated toStir at 90 ° C for 12 hours. After completion of the reaction, the mixture was filtered, and the filtrate was evaporated.The mixture was washed with water (30 mL×3)The title compound (yellow solid, 1.93 g, yield: 86percent).
References: [1] Patent: WO2005/105761, 2005, A1, . Location in patent: Page/Page column 36.
[2] Journal of Medicinal Chemistry, 2017, vol. 60, # 12, p. 5099 - 5119.
[3] Patent: WO2015/38417, 2015, A1, . Location in patent: Page/Page column 94; 95.
[4] Patent: CN108690043, 2018, A, . Location in patent: Paragraph 0262; 0266-0267.
[5] Chemical and Pharmaceutical Bulletin, 2001, vol. 49, # 4, p. 353 - 360.
  • 2
  • [ 455-88-9 ]
  • [ 112900-82-0 ]
References: [1] Chemical and Pharmaceutical Bulletin, 2001, vol. 49, # 4, p. 353 - 360.
[2] Patent: WO2015/38417, 2015, A1, .
[3] Journal of Medicinal Chemistry, 2017, vol. 60, # 12, p. 5099 - 5119.
[4] Patent: WO2005/105761, 2005, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 112900-82-0 ]

Aryls

Chemical Structure| 51013-67-3

A159079 [51013-67-3]

4-(Morpholinomethyl)aniline

Similarity: 0.88

Chemical Structure| 58028-76-5

A352413 [58028-76-5]

2-Morpholinobenzaldehyde

Similarity: 0.85

Chemical Structure| 280556-71-0

A118037 [280556-71-0]

(4-Morpholin-4-yl-phenyl)methanol

Similarity: 0.84

Chemical Structure| 2524-67-6

A293338 [2524-67-6]

4-Morpholinoaniline

Similarity: 0.81

Chemical Structure| 92-53-5

A219771 [92-53-5]

4-Phenylmorpholine

Similarity: 0.81

Amines

Chemical Structure| 51013-67-3

A159079 [51013-67-3]

4-(Morpholinomethyl)aniline

Similarity: 0.88

Chemical Structure| 3077-12-1

A139257 [3077-12-1]

2,2'-(p-Tolylazanediyl)diethanol

Similarity: 0.81

Chemical Structure| 2524-67-6

A293338 [2524-67-6]

4-Morpholinoaniline

Similarity: 0.81

Chemical Structure| 262368-47-8

A111728 [262368-47-8]

4-(2-Morpholinoethyl)aniline

Similarity: 0.80

Chemical Structure| 159724-40-0

A104719 [159724-40-0]

3-(4-Morpholinyl)aniline

Similarity: 0.79

Related Parent Nucleus of
[ 112900-82-0 ]

Morpholines

Chemical Structure| 51013-67-3

A159079 [51013-67-3]

4-(Morpholinomethyl)aniline

Similarity: 0.88

Chemical Structure| 58028-76-5

A352413 [58028-76-5]

2-Morpholinobenzaldehyde

Similarity: 0.85

Chemical Structure| 280556-71-0

A118037 [280556-71-0]

(4-Morpholin-4-yl-phenyl)methanol

Similarity: 0.84

Chemical Structure| 1646152-53-5

A268044 [1646152-53-5]

4-(Indolin-5-yl)morpholine hydrochloride

Similarity: 0.82

Chemical Structure| 92-53-5

A219771 [92-53-5]

4-Phenylmorpholine

Similarity: 0.81